Neuroscience

With one of the strongest pipelines in the industry, Roche Neuroscience is developing medicines for a range of serious neurological diseases, including multiple sclerosis, Alzheimer’s disease, autism, spinal muscular atrophy, depression and Parkinson’s disease.

Find out more

Multiple sclerosis

MS is a disease of the central nervous system, estimated to affect 2.3 million people worldwide.

Alzheimer’s disease is a progressive, fatal brain disease and the most common cause of dementia.

Learn how we are breaking down barriers that prevent patients from joining clinical trials for spinal muscular atrophy.

By the numbers

2.3 million

people worldwide are affected by Multiple Sclerosis

The roles of B cells in MS

Recent clinical evidence suggests that B cells contribute to both the inflammatory and neurodegenerative aspects of the disease.

Find out how we determine whether new drugs, diagnostics or procedures in the laboratory are both safe and effective when used to diagnose or treat people.

Get up-to-date information about our Pharma and Diagnostics pipeline.

Neuroscience

Multiple sclerosis

Roche in Alzheimer’s disease

Spinal muscular atrophy

By the numbers

The roles of B cells in MS

Clinical trials

Pipeline